Literature DB >> 32851480

Synthesis, antiproliferative activity in cancer cells and DNA interaction studies of [Pt(cis-1,3-diaminocycloalkane)Cl2] analogs.

James D Hoeschele1, Jana Kasparkova2, Hana Kostrhunova2, Olga Novakova2, Jitka Pracharova2, Paul Pineau1, Viktor Brabec3.   

Abstract

The search for more effective platinum anticancer drugs has led to the design, synthesis, and preclinical testing of hundreds of new platinum complexes. This search resulted in the recognition and subsequent FDA approval of the third-generation Pt(II) anticancer drug, [Pt(1,2-diaminocyclohexane)(oxalate)], oxaliplatin, as an effective agent in treating colorectal and gastrointestinal cancers. Another promising example of the class of anticancer platinum(II) complexes incorporating the Pt(1,n-diaminocycloalkane) moiety is kiteplatin ([Pt(cis-1,4-DACH)Cl2], DACH = diaminocyclohexane). We report here our progress in evaluating the role of the cycloalkyl moiety in these complexes focusing on the synthesis, characterization, evaluation of the antiproliferative activity in tumor cells and studies of the mechanism of action of new [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes wherein the cis-1,3-diaminocycloalkane group contains the cyclobutyl, cyclopentyl, and cyclohexyl moieties. We demonstrate that [Pt(cis-1,3-DACH)Cl2] destroys cancer cells with greater efficacy than the other two investigated 1,3-diamminocycloalkane derivatives, or cisplatin. Moreover, the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes show selectivity toward tumor cells relative to non-tumorigenic normal cells. We also performed several mechanistic studies in cell-free media focused on understanding some early steps in the mechanism of antitumor activity of bifunctional platinum(II) complexes. Our data indicate that reactivities of the investigated [Pt(cis-1,3-diaminocycloalkane)Cl2] complexes and cisplatin with glutathione and DNA binding do not correlate with antiproliferative activity of these platinum(II) complexes in cancer cells. In contrast, we show that the higher antiproliferative activity in cancer cells of [Pt(cis-1,3-DACH)Cl2] originates from its highest hydrophobicity and most efficient cellular uptake.

Entities:  

Keywords:  Antitumor; Cellular uptake; DNA; Glutathione; Oxaliplatin; Pt(1,n-diaminocycloalkane) moiety

Mesh:

Substances:

Year:  2020        PMID: 32851480     DOI: 10.1007/s00775-020-01809-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  19 in total

1.  Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine.

Authors:  Olga Novakova; Barbora Liskova; Jana Vystrcilova; Tereza Suchankova; Oldrich Vrana; Pavel Starha; Zdenek Travnicek; Viktor Brabec
Journal:  Eur J Med Chem       Date:  2014-03-15       Impact factor: 6.514

2.  Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites.

Authors:  M Kochi; M Fujii; N Kanamori; T Kaiga; R Okubo; Y Mihara; T Takayama
Journal:  J Chemother       Date:  2011-02       Impact factor: 1.714

3.  Antileukemic properties of dichloro(1,2-diaminocyclohexane)platinum(II).

Authors:  G R Gale; E M Walker; L M Atkins; A B Smith; S J Meischen
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-03

4.  New platinum complexes with anti-tumour activity.

Authors:  T A Connors; M Jones; W C Ross; P D Braddock; A R Khokhar; M L Tobe
Journal:  Chem Biol Interact       Date:  1972-11       Impact factor: 5.192

5.  Kinetic study of the reaction of cisplatin with thiols.

Authors:  James C Dabrowiak; Jerry Goodisman; Abdul-Kader Souid
Journal:  Drug Metab Dispos       Date:  2002-12       Impact factor: 3.922

Review 6.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

7.  Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form.

Authors:  Y Kidani; K Inagaki; M Iigo; A Hoshi; K Kuretani
Journal:  J Med Chem       Date:  1978-12       Impact factor: 7.446

8.  Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand.

Authors:  Jana Kasparkova; Tereza Suchankova; Anna Halamikova; Lenka Zerzankova; Oldrich Vrana; Nicola Margiotta; Giovanni Natile; Viktor Brabec
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

9.  Anticancer kiteplatin pyrophosphate derivatives show unexpected target selectivity for DNA.

Authors:  Jana Kasparkova; Hana Kostrhunova; Vojtech Novohradsky; Jitka Pracharova; Alessandra Curci; Nicola Margiotta; Giovanni Natile; Viktor Brabec
Journal:  Dalton Trans       Date:  2017-10-24       Impact factor: 4.390

10.  Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.

Authors:  Roland Geyer; Uwe Nordemann; Andrea Strasser; Hans-Joachim Wittmann; Armin Buschauer
Journal:  J Med Chem       Date:  2016-04-05       Impact factor: 7.446

View more
  1 in total

1.  Novel cis-Pt(II) Complexes with Alkylpyrazole Ligands: Synthesis, Characterization, and Unusual Mode of Anticancer Action.

Authors:  Jana Kasparkova; Hana Kostrhunova; Vojtech Novohradsky; Аlexey A Logvinov; Viktor V Temnov; Nataliya E Borisova; Tatiana A Podrugina; Lenka Markova; Pavel Starha; Alexey A Nazarov; Viktor Brabec
Journal:  Bioinorg Chem Appl       Date:  2022-03-02       Impact factor: 7.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.